866-997-4948(US-Canada Toll Free)

Biliary Tumor Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Oncology

No. of Pages : 43 Pages


Global Markets Directs, \'Biliary Tumor Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Biliary Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Biliary Tumor. 

Biliary Tumor Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Biliary Tumor.
  • A review of the Biliary Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Biliary Tumor pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Biliary Tumor.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Biliary Tumor pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Biliary Tumor Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Biliary Tumor 7
Biliary Tumor Therapeutics under Development by Companies 9
Biliary Tumor Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Biliary Tumor Therapeutics Products under Development by Companies 15
Biliary Tumor Therapeutics Products under Investigation by Universities/Institutes 16
Companies Involved in Biliary Tumor Therapeutics Development 17
Novartis AG 17
Biliary Tumor Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
MEK-162 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Lapatinib - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Bevacizumab + Erlotinib Hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
gemcitabine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
S-1 + Cisplatin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Bevacizumab + Erlotinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Gemcitabine + Capecitabine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cetuximab + Gemcitabine + Oxaliplatin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
WT1 Peptide Vaccination + Gemcitabine + Cisplatin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Cisplatin + 5-Fluorouracil + Gemcitabine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Biliary Tumor Therapeutics Drug Profile Updates 39
Biliary Tumor Therapeutics - Dormant Products 40
Biliary Tumor Product Development Milestones 41
Featured News & Press Releases 41
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 41

Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Table


Number of Products Under Development for Biliary Tumor, H2 2012 7
Products under Development for Biliary Tumor Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Novartis AG, H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Biliary Tumor Therapeutics Drug Profile Updates 39
Biliary Tumor Therapeutics Dormant Products 40

List of Chart


Number of Products under Development for Biliary Tumor, H2 2012 7
Products under Development for Biliary Tumor Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *